<DOC>
	<DOC>NCT00002354</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give indinavir sulfate plus stavudine to HIV-infected patients who have already been treated with zidovudine.</brief_summary>
	<brief_title>A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: Prophylaxis with aerosolized pentamidine, topical antifungals, TMP / SMX, dapsone, or isoniazid. Patients must have: HIV infection. CD4 count 50 500 cells/mm3. Prior AZT use for more than 6 months OR documented intolerance to AZT with more than 6 months use of another antiHIV therapy other than d4T or any protease inhibitor. No active opportunistic infection or visceral Kaposi's sarcoma. NOTE: Patients with hemophilia may be enrolled at discretion of investigator. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Symptomatic neuropathy. Acute hepatitis. Concurrent Medication: Excluded: Antiretrovirals other than specified in protocol. Chronic therapy for an active opportunistic infection. Immunosuppressive therapy. Prior Medication: Excluded: Any prior protease inhibitor or d4T. Any nucleoside analogs within 2 weeks prior to study entry. Investigational agents or immunomodulators within 30 days prior to study entry. Required: More than 6 months of prior AZT unless intolerant, in which case more than 6 months of another antiHIV therapy (other than protease inhibitors or d4T).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 1996</verification_date>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
</DOC>